Literature DB >> 30635211

Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis.

Grace C Lee1, Cristina R Ferrone1, Parsia A Vagefi2, Raul N Uppot3, Kenneth K Tanabe1, Keith D Lillemoe1, Lawrence S Blaszkowsky4, Motaz Qadan5.   

Abstract

BACKGROUND: The most appropriate treatment for early-stage hepatocellular carcinoma (HCC) remains unclear. This study compared the association of resection versus ablation with overall survival (OS) in patients with early-stage HCC.
METHODS: Using the National Cancer Database (NCDB), patients diagnosed with stage I/II HCC between 2004 and 2014 were identified. Cox analysis was used to determine predictors of OS.
RESULTS: We identified 53,161 patients, of whom 15.9% underwent ablation and 14.5% underwent resection. Patients with fewer comorbidities, larger tumors, and private insurance were more likely to undergo resection. Resection was associated with significantly improved OS compared to ablation (HR 0.58, 95% CI 0.54-0.61, p < 0.001), at all tumor sizes (p < 0.05) and any degree of liver fibrosis (p < 0.05).
CONCLUSIONS: Resection of HCC tumors of all sizes and any degree of underlying fibrosis was associated with significantly improved OS compared with ablation. There was pronounced variability in the use of ablation versus resection for early-stage HCC.
SUMMARY: This study found that patients with early-stage hepatocellular carcinoma (HCC) have improved overall survival (OS) after surgical resection, compared to ablation, at all tumor sizes and any extent of liver disease. There were also marked variations in treatment patterns for early-stage HCC.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Hepatocellular carcinoma; NCDB; Resection; Survival

Mesh:

Year:  2019        PMID: 30635211      PMCID: PMC6571152          DOI: 10.1016/j.amjsurg.2018.12.067

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  29 in total

1.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Authors:  Tito Livraghi; Franca Meloni; Michele Di Stasi; Emanuela Rolle; Luigi Solbiati; Carmine Tinelli; Sandro Rossi
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

2.  Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma.

Authors:  Yong Fang; Wei Chen; Xiao Liang; Da Li; HaiZhou Lou; Renbiao Chen; Kaifeng Wang; HongMing Pan
Journal:  J Gastroenterol Hepatol       Date:  2014-01       Impact factor: 4.029

3.  Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function.

Authors:  Sung Noh Hong; Sun-Young Lee; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee; Dongil Choi; Hyo Keun Lim; Kwang-Woong Lee; Jae Won Joh
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

4.  Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama
Journal:  J Hepatol       Date:  2012-11-21       Impact factor: 25.083

Review 5.  Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

Authors:  Jean-Charles Nault; Olivier Sutter; Pierre Nahon; Nathalie Ganne-Carrié; Olivier Séror
Journal:  J Hepatol       Date:  2017-10-13       Impact factor: 25.083

6.  Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study.

Authors:  Zhen-Wei Peng; Xiao-Jun Lin; Yao-Jun Zhang; Hui-Hong Liang; Rong-Ping Guo; Ming Shi; Min-Shan Chen
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

7.  Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function.

Authors:  Jason B Liu; Talia B Baker; Nicholas R Suss; Mark S Talamonti; Kevin K Roggin; David J Winchester; Marshall S Baker
Journal:  Surgery       Date:  2017-09-01       Impact factor: 3.982

8.  Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Matteo Cescon; Antonio Colecchia; Giorgio Ercolani; Luigi Bolondi; Antonio D Pinna
Journal:  J Hepatol       Date:  2013-04-18       Impact factor: 25.083

9.  Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization.

Authors:  G Colella; R Bottelli; L De Carlis; C V Sansalone; G F Rondinara; A Alberti; L S Belli; F Gelosa; G M Iamoni; A Rampoldi; A De Gasperi; A Corti; E Mazza; P Aseni; A Meroni; A O Slim; M Finzi; F Di Benedetto; F Manochehri; M L Follini; G Ideo; D Forti
Journal:  Transpl Int       Date:  1998       Impact factor: 3.782

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  4 in total

Review 1.  Curative-Intent Therapies in Localized Hepatocellular Carcinoma.

Authors:  Cathal O'Leary; Mary Mahler; Michael C Soulen
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

2.  Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma.

Authors:  Chengzhang Li; Jiucheng Xu
Journal:  Int J Environ Res Public Health       Date:  2020-02-07       Impact factor: 3.390

Review 3.  The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update.

Authors:  Gianluca Malagraba; Mahdieh Yarmohammadi; Aadil Javed; Carles Barceló; Teresa Rubio-Tomás
Journal:  Biomolecules       Date:  2022-03-17

4.  The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma.

Authors:  Zhi-Yuan Chen; Zhi-Xing Guo; Liang-He Lu; Jie Mei; Wen-Ping Lin; Shao-Hua Li; Wei Wei; Rong-Ping Guo
Journal:  Cancer Med       Date:  2021-07-01       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.